Medical News

RSS

Boston Scientific adds 22 new balloon sizes to PolarCath Peripheral Dilatation System

Boston Scientific Corporation today announced that 22 new balloon sizes have been added to the PolarCath® Peripheral Dilatation System, including balloon lengths of 120 and 150 mm. The PolarCath System is used to restore blood flow in patients with critical limb ischemia (severe blockages in the arteries below the knee) and blockages in the femoral and popliteal (behind the knee) arteries. Both conditions result from peripheral artery disease.

21 Jun 2010

Today's OpEds: Medicare reimbursements threaten health care; Battling health care fraud; A national standard on nurse-patient ratios

The Senate on Friday passed the annual "doc fix" -- but this short-term stay on the reimbursement rates for physicians who treat Medicare patients does not resolve the underlying problem: Those reimbursements are woefully below market. And if Congress does not address this, the much-heralded health-care reform is at risk (Dr. Michael Newman, 6/19).

21 Jun 2010

FDA approves Abbott's ARCHITECT HIV Ag/Ab Combo assay

Every nine and a half minutes, someone in the United States is infected with HIV, and one out of every five of these individuals doesn't know it. To help stem the spread of this disease, the U.S. Food and Drug Administration (FDA) today approved an innovative new diagnostic tool, which will allow patients to be diagnosed earlier than ever before.

21 Jun 2010

Al Amal Hospital in Qatar commences treatment with Varian's RapidArc radiotherapy

One of the leading cancer centers in the Middle East has become among the first in the region to introduce fast and efficient RapidArc® radiotherapy treatments from Varian Medical Systems. Al Amal Hospital in Doha, Qatar, has treated nine brain cancer, prostate cancer and head & neck cancer patients with RapidArc since commencing treatments in early May, and it now plans to roll out the technology for many more indications.

21 Jun 2010

Ferring announces availability of LYSTEDA for cyclic heavy menstrual bleeding in U.S.

Ferring Pharmaceuticals Inc. announced today the U.S. commercial availability of LYSTEDA™ (tranexamic acid) tablets, the only non-hormonal and non-surgical therapy indicated specifically for the treatment of women with cyclic heavy menstrual bleeding (HMB). In clinical studies, LYSTEDA significantly reduced menstrual blood loss (MBL) over three and six cycles of use with the reduction seen as early as the first cycle of use.

21 Jun 2010

"Lap Band" weight loss surgery improves physical, psychological health in extremely obese adults

One year after weight loss surgery with laparoscopic gastric banding, extremely obese adults demonstrate not only better physical health but also improved psychological health, a new study shows. The results will be presented Monday at The Endocrine Society's 92nd Annual Meeting in San Diego.

21 Jun 2010

Select Medical to acquire Regency Hospital

Select Medical Holdings Corporation, the parent of Select Medical Corporation, today announced the signing of a definitive agreement to acquire all of the issued and outstanding equity securities of Regency Hospital Company, L.L.C., an operator of long-term acute care hospitals, for approximately $210 million, including certain assumed liabilities. Regency is a portfolio company of Waud Capital Partners.

21 Jun 2010

Keane Healthcare Solutions Division announces partnership with Ormed Information Systems

Keane, Inc., a U.S.-based IT services and healthcare technology firm, today announced a partnership between its Healthcare Solutions Division (HSD) and Ormed Information Systems, Ltd. against the backdrop of the Healthcare Financial Management Annual National Institute conference (HFMA ANI). Ormed is a leading supplier of human resources, supply chain, E-commerce, and accounting management software, and is entering their 21st year in supporting only the healthcare industry.

21 Jun 2010

Imagenetix reports net loss of $697,000 for fiscal 2010

Imagenetix, Inc. announced today results for its fiscal year ended March 31, 2010. Net sales decreased 12% for the year to $6,596,000 from the $7,461,000 reported for the same period last year.

21 Jun 2010

Independent DMC recommends continuation of BioSante's ongoing LibiGel CV and Breast Cancer Safety Study

BioSante Pharmaceuticals, Inc., today announced that the independent Data Monitoring Committee (DMC) of the ongoing LibiGel® Cardiovascular (CV) and Breast Cancer Safety Study unanimously recommended study continuation without modifications, after its third review of the study's unblinded safety data. The review was based on data from almost 1,500 women-years of exposure.

21 Jun 2010

KHN column: Even with the 'grandfather clause' protection, change is coming to most health plans

In his latest Kaiser Health News column, done in collaboration with The New Republic, Jonathan Cohn writes: "Now that Karl Rove doesn't have a Republican president to advise anymore, he's been picking up some new hobbies. One of them is health care policy. In a recent column for the Wall Street Journal editorial page, Rove made the latest in a series of attacks on the new reform law.

21 Jun 2010

BioSante announces $15 million registered direct offering

BioSante Pharmaceuticals, Inc. today announced that it has received commitments from several institutional investors to purchase $15 million of securities in a registered direct offering. The investors are Deerfield Management Company and other institutional investors. BioSante expects to receive net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses.

21 Jun 2010

Palatin reports preclinical study results of PL-3994 in respiratory tissue for asthma indications

Palatin Technologies, Inc. today announced results of preclinical studies in respiratory tissue with PL-3994. In rat, guinea pig and human tissues, PL-3994 produced potent relaxation of isolated airway smooth muscle, indicating that PL-3994 may be a potent bronchodilator in humans.

21 Jun 2010

Emdeon's Assistant, Claim Master solutions earn HFMA Peer Reviewed designation

Emdeon Inc., a leading provider of healthcare revenue and payment cycle management solutions, today announced that its automated patient eligibility and benefits verification tool, Emdeon® Assistant™, and web-based billing management solution, Emdeon Claim Master®, have earned the Peer Reviewed designation of the Healthcare Financial Management Association (HFMA). The HFMA Peer Reviewed designation places these Emdeon solutions on a short list of prestigious products that have been proven effective by industry expert volunteers and independent HFMA staff.

21 Jun 2010

Saladax Biomedical, Bristol-Myers Squibb collaborate to develop clinical diagnostics

Saladax Biomedical, Inc. announced today that it has entered into a multi-year development and commercialization agreement with Bristol-Myers Squibb Company for the development of certain clinical diagnostic tests to be used in conjunction with the development of certain therapeutic compounds in the Bristol-Myers Squibb pipeline.

21 Jun 2010

First StemSource Cell Bank in U.S. open

BioLife Cell Bank, LLC has opened the first U.S. StemSource® Cell Bank, which offers patients a way to safely and affordably store their own adipose (fat) tissue or their own naturally occurring adipose (fat) tissue-derived stem and regenerative cells. This gives patients and physicians easy, multi-use access to cells and tissue for future approved or allowed reconstructive fat grafting or augmentation procedures using the patients' own cells and/or tissue.

21 Jun 2010

Dako, Omnyx partner to develop clinical algorithms for digital pathology

Dako, a Danish-based world leader in tissue-based cancer diagnostics, and Omnyx, a leader in digital pathology solutions, announced today that they have entered into a three-year agreement to develop clinical algorithms for digital pathology. The aim is to support pathologists in generating even more accurate, objective and reproducible diagnostic results.

21 Jun 2010

Simulations Plus third-quarter consolidated preliminary revenues up 14.9% to $3.1M

Simulations Plus, Inc., a leading provider of software for pharmaceutical discovery and development, today released preliminary revenues for its third fiscal quarter ended May 31, 2010.

21 Jun 2010

Essen BioScience, Nycomed partner to develop modulators of voltage-gated ion channels

Essen BioScience Inc. - a specialty provider of cell-based assay solutions and contract research services - and Nycomed - a privately owned global pharmaceutical company headquartered in Zurich, Switzerland - are pleased to announce a joint discovery agreement to identify novel small molecule ion channel modulators as pain therapeutics.

From Sartorius 21 Jun 2010

FDA grants Pathway 510(k) clearance for JETSTREAM G3 SF peripheral revascularization catheter for PVD

Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral vascular disease (PVD), today announced that the U.S. Food & Drug Administration (FDA) has granted the company 510(k) clearance to market JETSTREAM G3™ SF (Small Fixed), the newest version of its peripheral revascularization catheter for the treatment of PVD.

21 Jun 2010

Medical News

Boston Scientific adds 22 new balloon sizes to PolarCath Peripheral Dilatation System

Today's OpEds: Medicare reimbursements threaten health care; Battling health care fraud; A national standard on nurse-patient ratios

FDA approves Abbott's ARCHITECT HIV Ag/Ab Combo assay

Al Amal Hospital in Qatar commences treatment with Varian's RapidArc radiotherapy

Ferring announces availability of LYSTEDA for cyclic heavy menstrual bleeding in U.S.

"Lap Band" weight loss surgery improves physical, psychological health in extremely obese adults

Select Medical to acquire Regency Hospital

Keane Healthcare Solutions Division announces partnership with Ormed Information Systems

Imagenetix reports net loss of $697,000 for fiscal 2010

Independent DMC recommends continuation of BioSante's ongoing LibiGel CV and Breast Cancer Safety Study

KHN column: Even with the 'grandfather clause' protection, change is coming to most health plans

BioSante announces $15 million registered direct offering

Palatin reports preclinical study results of PL-3994 in respiratory tissue for asthma indications

Emdeon's Assistant, Claim Master solutions earn HFMA Peer Reviewed designation

Saladax Biomedical, Bristol-Myers Squibb collaborate to develop clinical diagnostics

First StemSource Cell Bank in U.S. open

Dako, Omnyx partner to develop clinical algorithms for digital pathology

Simulations Plus third-quarter consolidated preliminary revenues up 14.9% to $3.1M

Essen BioScience, Nycomed partner to develop modulators of voltage-gated ion channels

FDA grants Pathway 510(k) clearance for JETSTREAM G3 SF peripheral revascularization catheter for PVD

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News